Teratogenic valproic acid concentrations: Infusion by implanted minipumps vs conventional injection regimen in the mouse

https://doi.org/10.1016/0041-008X(85)90081-XGet rights and content

Abstract

The dosage-regimen-dependent teratogenicity as well as plasma and tissue levels of the antiepileptic drug valproic acid (VPA) were studied in the mouse by comparing various injection regimens and infusion of the drug via implanted osmotic minipumps. Concentrations of 225–248 μg VPA/ml maternal plasma (about 2× above the therapeutic concentration range) and 70–75 μg VPA/g gestational material (on gestation Day 8) resulted in a significant incidence of neural tube defects (exencephaly in the mouse). Similar effects were produced if those concentrations were reached several times after multiple injections or by steady-state application via implanted pumps. A single injection was less effective than multiple injections, although drug accumulation did not occur. The doses (or area under the concentration-time curve values) did not correlate with the teratogenic response of the different administration regimens: much higher (factor 10) doses were needed with the infusion regimen to produce exencephaly rates comparable to those obtained with the injection regimen. The pattern of embryotoxicity was also schedule dependent: steady-state concentrations produced predominantly embryolethality and fetal weight retardation, while intermittent injectionssproduced a high incidence of exencephaly (up to 60% of live fetuses). The dose of VPA (and the areas under the concentration-time curves) correlated with the embryolethality and fetal weight retardation of the drug, while the peak or steady-state concentrations reached in mother and gestational material correlated with the incidence of neural tube defects.

References (25)

  • I. Gjerloff et al.

    Monodose versus 3 daily doses of sodium valproate: A controlled trial

    Acta Neurol. Scand.

    (1984)
  • R. Gugler et al.

    Clinical pharmacokinetics of valproic acid

    Clin. Pharmacokin.

    (1980)
  • Cited by (138)

    • Toxicologic pathology of the reproductive system

      2022, Reproductive and Developmental Toxicology
    • Role of Cbp, p300 and Akt in valproic acid induced neural tube defects in CD-1 mouse embryos

      2020, Reproductive Toxicology
      Citation Excerpt :

      Neural folds are formed at the edges of the neural plate which progress toward the midline and fuse to form the NT, the structure that subsequently develops into the brain and spinal cord [7]. One of the mechanisms resulting in neural tube defects is the failure of the NT to close at the midline, thus remaining open at any point between the cranial to caudal ends [8]. The incidence of NTDs, including anencephaly/exencephaly and lumbosacral meningomyelocele, is 1–2% in VPA-exposed human pregnancies [9].

    • Embryology and teratology

      2019, The Laboratory Rat
    • Valproic acid disrupts the biomechanics of late spinal neural tube closure in mouse embryos

      2018, Mechanisms of Development
      Citation Excerpt :

      Evidence for this includes the distal spina bifida caused by in utero exposure to the anti-epileptic medication valproic acid (VPA) (Robert and Guibaud, 1982; Van Allen et al., 1993). In mice, exposure to VPA during neurulation also impairs NT closure, but the resulting defects primarily affect the cranial region causing exencephaly (the developmental forerunner of anencephaly) (Nau, 1985; Nau and Loscher, 1986). These teratogenic effects are distinct from VPA's anti-epileptic properties as not all of its anti-epileptic metabolites and analogues cause exencephaly when injected into mice (Nau and Loscher, 1986).

    • Adverse effects of prenatal and early postnatal exposure to antiepileptic drugs: Validation from clinical and basic researches

      2017, Brain and Development
      Citation Excerpt :

      As for structural anomalies within the central nervous system, prenatal exposure to VPA is known to induce neural tube defects [53], neuronal migration defects leading to the impairment of neocortical lamination [54], increased weight of the whole brain [55], increased density of prefrontal neocortical neurons [56], apoptosis in the developing embryonic cerebral wall [57], and reduced adult neuronogenesis in the hippocampi [58]. It is important to note that these previous observations may not represent the effects of prenatal exposure to VPA in humans, since VPA was administered to pregnant rodents at high-dose (generally 400–500 mg/kg/dose; approximately twice the median effective dose (ED50), see Table 1), in a single or in multiple injections during the middle phase of embryogenesis, that is, usually on embryonic day 11 (E11) or E12, despite the short half-life of VPA in rodents (1–2 h) [53]. Thus, in more recent analyses, VPA was administrated to pregnant rodents at lower dosages for longer periods so as to reproduce the in utero environment in human epileptic mothers taking VPA.

    View all citing articles on Scopus
    View full text